Overview of Dr. Funt

Dr. Samuel Funt is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan-Kettering Cancer Center, Memorial Hospital for Cancer and allied Diseases, Memorial Hospital for Cancer and allied Diseases, and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Emory University School of Medicine and has been in practice 7 years. He is one of 468 doctors at Memorial Sloan-Kettering Cancer Center and one of 82 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He also speaks multiple languages, including Spanish. He has more than 60 publications and over 500 citings.

Education & Training

• Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2014 - 2016

• New York Presbyterian Hospital (Columbia Campus)Chief Residency, Internal Medicine, 2013 - 2014

• New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2010 - 2013

• Emory University School of MedicineClass of 2010

Certifications & Licensure

• FL State Medical License 2021 - Present

• NJ State Medical License 2019 - 2025

• CT State Medical License 2023 - 2024

• PA State Medical License 2022 - 2024

• NY State Medical License 2011 - 2024

• NC State Medical License 2021 - 2022

• American Board of Internal Medicine Internal Medicine
• American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

• Patient-Centered Medical Home Recognition Program National Committee for Quality Assurance, 2013-2016

Clinical Trials

Publications & Presentations

PubMed

• Ototoxicity associated with high-dose carboplatin for patients with previously treated germ cell tumors.

  Samuel A Funt, Andrea Knezevic, Kaamilah Wilson, Maria Bromberg, Amy Budnick, Kerri L O'Connor, Deaglan J McHugh, Erik Larsen, Dean F Bajorin, Robert J Motzer, Emily S...> ;Cancer. 2023 Dec 15
• 1 citations

  Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.

  Brendan J Guercio, Michal Sarfaty, Min Yuen Teo, Neha Ratna, Cihan Duzgol, Samuel A Funt, Chung-Han Lee, David H Aggen, Ashley M Regazzi, Ziyu Chen, Michael Lattanzi, ...> ;Clinical Cancer Research. 2023 Nov 14

• Primary Retroperitoneal Lymph Node Dissection for Seminoma Metastatic to the Retroperitoneum.

  Richard S Matulewicz, Nicole Benfante, Samuel A Funt, Darren R Feldman, Brett Carver, Alexander Doudt, Andrea Knezevic, Joel Sheinfeld> ;The Journal of Urology. 2024 Jan 1
• Join now to see all

Lectures

• A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC). 

  2019 ASCO Annual Meeting - 6/1/2019

• Etoposide and cisplatin (EP) for metastatic good-risk germ cell tumors (GCTs): The Memorial Sloan-Kettering Cancer Center (MSKCC) experience in 944 patients (pts). 

  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

• Neoadjuvant Atezolizumab–Chemotherapy ‘Worthy of Investigation’ for MIBCFebruary 14th, 2022

• A Pipeline to a Medical CareerAugust 19th, 2021

• Neoadjuvant Atezolizumab with Gemcitabine and Cisplatin in Patients with Muscle-Invasive Bladder Cancer - Samuel A. FuntJuly 29th, 2021

• Join now to see all

Other Languages

Hospital Affiliations